The safety and efficacy of Yokukansan in treating neuropsychiatric symptoms of patients with Fronto-Temporal Lobar Degeneration (FTLD)
- Conditions
- Fronto-Temporal Lobar Degeneration (FTLD)
- Registration Number
- JPRN-UMIN000001897
- Lead Sponsor
- Ehime University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 20
Not provided
1) Patients with concomitant diagnosis of malignant cancer. 2) Patients with concomitant diagnosis o sevious heart, liver, lung or kidney disease, blood disorders, or other life-threatening diseases. 3) Ptients with other forms of dementia (AD, VD, DLB) besides Fronto-Temporal Degeneration (FTLD) 4) Patients who fail to meet the DSM-IV diagnostic criteria for our study, but show symptoms of BPSD due to other concomitant neurodegerative disease, Scizophrenia, Bipolar disorder, Major depressive disorder or other psychiatric disorders. 5) Patients with delirium due to alcohol or drug addicution, metabolic poisoning, or inflammatory disease. 6) Patients who are unable to take oral medications. 7) Patients who altered their dosage or method of administration of SSRI, 8 weeks before the start of the study. 8) Ptients who took long acting antipsychotic durgs (such as haloperidol decanoate) 4 weeks before the start of treatment. 9) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PI-D
- Secondary Outcome Measures
Name Time Method SRI, Barthel Index, Zaril Caregiver Burden Scale MMSE, swallowing ability, appetite level, questionnaire regarding eating patterns, cerebral blood flow